Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for PROCEPT BioRobotics (PRCT) over the last 6 years, with Q3 2025 value amounting to $5.5 million.

  • PROCEPT BioRobotics' Change in Accured Expenses rose 3803.14% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year decrease of 4258.09%. This contributed to the annual value of $4.7 million for FY2024, which is 3531.12% up from last year.
  • Latest data reveals that PROCEPT BioRobotics reported Change in Accured Expenses of $5.5 million as of Q3 2025, which was up 3803.14% from $1.3 million recorded in Q2 2025.
  • PROCEPT BioRobotics' Change in Accured Expenses' 5-year high stood at $5.5 million during Q3 2025, with a 5-year trough of -$6.6 million in Q1 2025.
  • In the last 5 years, PROCEPT BioRobotics' Change in Accured Expenses had a median value of $2.5 million in 2021 and averaged $934105.3.
  • As far as peak fluctuations go, PROCEPT BioRobotics' Change in Accured Expenses soared by 47325.06% in 2022, and later tumbled by 21969.3% in 2023.
  • Quarter analysis of 5 years shows PROCEPT BioRobotics' Change in Accured Expenses stood at $1.7 million in 2021, then surged by 88.78% to $3.2 million in 2022, then decreased by 1.36% to $3.1 million in 2023, then dropped by 13.34% to $2.7 million in 2024, then surged by 101.81% to $5.5 million in 2025.
  • Its Change in Accured Expenses was $5.5 million in Q3 2025, compared to $1.3 million in Q2 2025 and -$6.6 million in Q1 2025.